Medicina
Facultad
JOSÉ ANTONIO
RAMOS ATANCE
Investigador hasta 2020
Publicaciones en las que colabora con JOSÉ ANTONIO RAMOS ATANCE (165)
2023
-
El gen del receptor cannabinoide tipo 2 se asocia con la comorbilidad entre esquizofrenia y dependencia de cannabis y el gen de la enzima amidohidrolasa de ácidos grasos se asocia con la dependencia de cannabis en población española
Adicciones: Revista de socidrogalcohol, Vol. 35, Núm. 1, pp. 33-45
2018
-
Cannabinoid pharmacology/therapeutics in chronic degenerative disorders affecting the central nervous system
Biochemical Pharmacology, Vol. 157, pp. 67-84
2017
-
Altered striatal endocannabinoid signaling in a transgenic mouse model of spinocerebellar ataxia type-3
PLoS ONE, Vol. 12, Núm. 4
-
Modeling Neurodegenerative Disorders for Developing Cannabinoid-Based Neuroprotective Therapies
Methods in Enzymology (Academic Press Inc.), pp. 175-198
2016
2015
-
Changes in the endocannabinoid signaling system in CNS structures of TDP-43 transgenic mice: relevance for a neuroprotective therapy in TDP-43-related disorders
Journal of Neuroimmune Pharmacology, Vol. 10, Núm. 2, pp. 233-244
2012
-
Cannabinoids ameliorate disease progression in a model of multiple sclerosis in mice, acting preferentially through CB1 receptor-mediated anti-inflammatory effects
Neuropharmacology, Vol. 62, Núm. 7, pp. 2299-2308
2011
-
Neuroprotective effects of phytocannabinoid-based medicines in experimental models of Huntington's disease
Journal of Neuroscience Research, Vol. 89, Núm. 9, pp. 1509-1518
-
New serotonin 5-HT 1A receptor agonists with neuroprotective effect against ischemic cell damage
Journal of Medicinal Chemistry, Vol. 54, Núm. 23, pp. 7986-7999
-
Pharmacological activation/inhibition of the cannabinoid system affects alcohol withdrawal-induced neuronal hypersensitivity to excitotoxic insults
PLoS ONE, Vol. 6, Núm. 8
-
Prospects for cannabinoid therapies in basal ganglia disorders
British Journal of Pharmacology, Vol. 163, Núm. 7, pp. 1365-1378
-
Symptom-relieving and neuroprotective effects of the phytocannabinoid Δ 9-THCV in animal models of Parkinson's disease
British Journal of Pharmacology, Vol. 163, Núm. 7, pp. 1495-1506
2010
-
Cannabinoid-dopamine interaction in the pathophysiology and treatment of CNS disorders
CNS Neuroscience and Therapeutics, Vol. 16, Núm. 3
-
Gender-specific COMT Val158Met polymorphism association in Spanish schizophrenic patients
American Journal of Medical Genetics, Part B: Neuropsychiatric Genetics, Vol. 153, Núm. 1, pp. 79-85
2009
-
Actualización sobre el potencial terapéutico de los cannabinoides
Sociedad Española de Investigación en Cannabinoides (SEIC)
-
Effects of a short-term exposure to alcohol in rats on FAAH enzyme and CB1 receptor in different brain areas
Drug and Alcohol Dependence, Vol. 99, Núm. 1-3, pp. 354-358
-
Lack of association between polymorphisms in cannabinoid receptor gene (CNR1) and fatty acid amide hydroxylase gene (FAAH) and eating disorders in a preliminary study
Psychiatric Genetics, Vol. 19, Núm. 6, pp. 336
2008
-
CB1 receptor blockade reduces the anxiogenic-like response and ameliorates the neurochemical imbalances associated with alcohol withdrawal in rats
Neuropharmacology, Vol. 54, Núm. 6, pp. 976-988
-
Role of CB2 receptors in neuroprotective effects of cannabinoids
Molecular and Cellular Endocrinology, Vol. 286, Núm. 1-2 SUPPL. 1
2007
-
Association in alcoholic patients between psychopathic traits and the additive effect of allelic forms of the CNR1 and FAAH endocannabinoid genes, and the 3′ region of the DRD2 gene
Neurotoxicity Research, Vol. 11, Núm. 1, pp. 51-59